HemoGenyx Pharmaceuticals Plc (LSE:HEMO) attracts attention through its exposure to experimental therapies and cell-based treatments.
Ondine Biomedical, Inc. (LSE:OBI) attracts attention through its exposure to photodisinfection technologies for infection prevention.
NIOX Group plc (LSE:NIOX) is in focus for investors assessing the latest outlook for the healthcare sector as of 27 October 2026. The central question is not simply whether the business attracts attention, but whether its operating performance, financial position and near-term milestones can …
PureTech Health plc (LSE:PRTC) is in focus for investors assessing the latest outlook for the healthcare sector as of 27 October 2026. The central question is not simply whether the business attracts attention, but whether its operating performance, financial position and near-term milestones can …
Faron Pharmaceuticals Ltd is a Turku-based clinical-stage biopharmaceutical company developing immunotherapies for cancer, with shares quoted on AIM under the ticker LSE:FARN.
HemoGenyx Pharmaceuticals Plc (LSE:HEMO) gained 4.29% on 27 October 2026 as investors responded to news from its pre-clinical research programme. Early-stage pharmaceutical shares are highly sensitive to research updates. HemoGenyx focuses on disorders of the blood that represent significant unmet medical need, and progress …
ImmuPharma plc (LSE:IMM) is a UK-listed clinical-stage biopharmaceutical company developing novel approaches to autoimmune diseases, with SLE as its primary indication. Its lead programme, Lupuzor, uses the P140 peptide, a tolerogenic immunotherapy designed to address the immune dysfunction driving lupus. On 27 October 2026, …
Inspiration Healthcare Group PLC (LSE:IHC) gained 8.11% on 27 October, 2026, as attention turned to its position in neonatal and critical care devices. The AIM-listed company supplies technologies used in neonatal units, emergency departments and critical care settings, serving premature and critically ill newborns …
Eden BioSolutions PLC (LSE:EDEN) is a UK-listed biopesticide developer bringing biological and naturally derived crop protection products to global agricultural markets. Its platform targets a structural shift away from synthetic chemical inputs toward solutions meeting tightening regulatory and consumer residue standards. On 27 October …
The advance appears to reflect company developments and sector tailwinds. A recent stock exchange announcement outlined progress in clinical testing partnerships, with new agreements enabling expanded testing volumes at several laboratory sites. The market responded to signs that the commercial pipeline is translating into …